病毒清除市场－全球产业规模、份额、趋势、机会和预测，按应用、方法、最终用户、地区和竞争格局划分，2020-2030年预测

全球病毒清除市场规模将从2024年的7.7334亿美元成长至2030年的12.6323亿美元，年复合成长率达8.52%。全球病毒清除市场涵盖一系列专业产品和服务，旨在透过在生产过程中检测、去除或灭活潜在的病毒污染物，确保生物製药产品（包括治疗性蛋白质、疫苗和先进疗法）的病毒安全性。市场扩张的主要驱动力是全球对复杂生物製剂的需求不断增长，以及世界各国卫生监管机构为确保产品纯度和患者安全而日益严格的监管要求。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球病毒清除市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依应用领域（重组蛋白、血液、疫苗、其他）
  • 按方法（病毒去除法、病毒灭活法、病毒检测法）
  • 按最终用户（製药和生物技术公司、合约研究组织、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美病毒清除市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲病毒清除市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区病毒清除市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲病毒清除市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美病毒清除市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球病毒清除市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Charles River Laboratories International, Inc.
• Wuxi Biologics Inc
• Eurofins Scientific SE
• Sartorius AG
• Texcell, Inc.
• Biosafety Testing Services, Inc.
• Avance Biosciences Laboratories Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Viral Clearance Market will grow from USD 773.34 Million in 2024 to USD 1263.23 Million by 2030 at a 8.52% CAGR. The global viral clearance market comprises specialized products and services designed to ensure the viral safety of biopharmaceutical products, including therapeutic proteins, vaccines, and advanced therapies, by detecting, removing, or inactivating potential viral contaminants during manufacturing. Market expansion is primarily driven by the escalating global demand for complex biologics and the increasingly stringent regulatory requirements imposed by health authorities worldwide to ensure product purity and patient safety.

Key Market Drivers

The global viral clearance market is significantly driven by the expanding biopharmaceutical and biologics pipeline, which continually introduces a greater volume and diversity of products necessitating stringent viral safety assurance. As pharmaceutical companies intensify research and development efforts, particularly in advanced therapies, the demand for robust viral clearance solutions escalates across all manufacturing stages, from cell line development to final product formulation. The inherent complexity of novel biologics, including cell and gene therapies, mandates sophisticated viral clearance strategies to meet evolving product specifications and ensure patient safety. According to J.P. Morgan, in December 2024, their '2024 Biopharma Industry Insights: Investment Trends, M&A Activity, and Market Dynamics' report indicated that biologics investment for seed and series A rounds reached $3.5 billion, underscoring the substantial financial commitment fueling this pipeline expansion and, consequently, the demand for viral clearance technologies.

Key Market Challenges

A significant challenge impeding the expansion of the global viral clearance market is the substantial investment and specialized technical expertise necessary for developing and validating effective viral clearance strategies, especially for new and varied biopharmaceutical products. This requirement places a considerable financial burden on manufacturers, particularly for smaller and emerging companies, limiting their capacity to adopt or innovate in viral clearance technologies. The complexity associated with ensuring viral safety for novel modalities, such as gene therapies or advanced protein therapeutics, demands extensive research and development resources, along with highly skilled personnel to navigate intricate regulatory pathways and perform rigorous validation studies.

Key Market Trends

The global viral clearance market is significantly influenced by the strategic shift towards integrating viral clearance assessments into the early stages of drug development. This proactive approach aims to identify and mitigate potential viral risks much sooner, ultimately streamlining the development timeline and reducing costly delays in later phases. Early consideration of viral clearance strategies also allows for the optimization of purification processes from the outset, ensuring regulatory compliance and product safety as a core component of the development paradigm rather than an afterthought. According to the Food and Drug Administration's Center for Drug Evaluation and Research, in June 2025, their "Analysis of Virus Clearance for Biotechnology Manufacturing Processes from Early to Late Phase Development" article highlighted that the risk for virus contamination in biotechnology products derived from mammalian cell lines must be evaluated from the early stages of development, underscoring this trend's regulatory and scientific importance.

Key Market Players

• Charles River Laboratories International, Inc.
• Wuxi Biologics Inc
• Eurofins Scientific SE
• Sartorius AG
• Texcell, Inc.
• Biosafety Testing Services, Inc.
• Avance Biosciences Laboratories Inc.

Report Scope:

In this report, the Global Viral Clearance Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Viral Clearance Market, By Application:

• Recombinant Proteins
• Blood
• Vaccines
• Others

Viral Clearance Market, By Method:

• Viral Removal Method
• Viral Inactivation Method
• Viral Detection Method

Viral Clearance Market, By End User:

• Pharmaceutical & Biotechnology Companies
• CROs
• Others

Viral Clearance Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Viral Clearance Market.

Available Customizations:

Global Viral Clearance Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Viral Clearance Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Application (Recombinant Proteins, Blood, Vaccines, Others)
  • 5.2.2. By Method (Viral Removal Method, Viral Inactivation Method, Viral Detection Method)
  • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, CROs, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Viral Clearance Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Application
  • 6.2.2. By Method
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Viral Clearance Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Application
      • 6.3.1.2.2. By Method
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Viral Clearance Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Application
      • 6.3.2.2.2. By Method
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Viral Clearance Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Application
      • 6.3.3.2.2. By Method
      • 6.3.3.2.3. By End User

7. Europe Viral Clearance Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Application
  • 7.2.2. By Method
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Viral Clearance Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Application
      • 7.3.1.2.2. By Method
      • 7.3.1.2.3. By End User
  • 7.3.2. France Viral Clearance Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Application
      • 7.3.2.2.2. By Method
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Viral Clearance Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Application
      • 7.3.3.2.2. By Method
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Viral Clearance Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Application
      • 7.3.4.2.2. By Method
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Viral Clearance Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Application
      • 7.3.5.2.2. By Method
      • 7.3.5.2.3. By End User

8. Asia Pacific Viral Clearance Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Application
  • 8.2.2. By Method
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Viral Clearance Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Application
      • 8.3.1.2.2. By Method
      • 8.3.1.2.3. By End User
  • 8.3.2. India Viral Clearance Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Application
      • 8.3.2.2.2. By Method
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Viral Clearance Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Application
      • 8.3.3.2.2. By Method
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Viral Clearance Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Application
      • 8.3.4.2.2. By Method
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Viral Clearance Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Application
      • 8.3.5.2.2. By Method
      • 8.3.5.2.3. By End User

9. Middle East & Africa Viral Clearance Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Application
  • 9.2.2. By Method
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Viral Clearance Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Application
      • 9.3.1.2.2. By Method
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Viral Clearance Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Application
      • 9.3.2.2.2. By Method
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Viral Clearance Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Application
      • 9.3.3.2.2. By Method
      • 9.3.3.2.3. By End User

10. South America Viral Clearance Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Application
  • 10.2.2. By Method
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Viral Clearance Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Application
      • 10.3.1.2.2. By Method
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Viral Clearance Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Application
      • 10.3.2.2.2. By Method
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Viral Clearance Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Application
      • 10.3.3.2.2. By Method
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Viral Clearance Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Charles River Laboratories International, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Wuxi Biologics Inc
• 15.3. Eurofins Scientific SE
• 15.4. Sartorius AG
• 15.5. Texcell, Inc.
• 15.6. Biosafety Testing Services, Inc.
• 15.7. Avance Biosciences Laboratories Inc.

16. Strategic Recommendations

17. About Us & Disclaimer